短程放疗联合替莫唑胺治疗老年新诊断胶质母细胞瘤的生存荟萃分析
该研究通过检索PubMed、SCOPUS和Embase,纳入5项研究共1062例≥65岁新诊断胶质母细胞瘤患者,比较短程放疗(SCRT)联合或不联合替莫唑胺(TMZ)的疗效。结果显示SCRT+TMZ显著降低死亡风险(HR 0.68)和疾病进展风险(HR 0.53),中位总生存期(8.0 vs 6.1个月)和无进展生存期(5.1 vs 3.8个月)均延长,且生存获益随时间增加。
要点
- SCRT+TMZ较单纯SCRT显著改善老年胶质母细胞瘤患者的总生存期和无进展生存期。
- 生存获益随时间累积,30个月时总生存期RMST增益达2.50个月。
- 需更多临床试验补充证据,尤其针对体能状态较差老年人群。
核心结论
- 在老年新诊断胶质母细胞瘤患者中,SCRT+TMZ较单纯SCRT显著改善总生存期和无进展生存期,且生存获益随时间增加。
研究设计与样本
- 本研究为时间-事件荟萃分析,检索PubMed、SCOPUS和Embase至2025年7月9日,纳入5项直接比较SCRT与SCRT+TMZ的研究,共1062例患者(SCRT+TMZ组516例,SCRT组546例)。
主要发现
- SCRT+TMZ显著降低死亡风险(HR 0.68,95% CI 0.70–0.77;p < 0.0001)和疾病进展风险(HR 0.53,95% CI 0.45–0.62;p < 0.0001)。
- SCRT+TMZ组中位总生存期为8.0个月,单纯SCRT组为6.1个月;中位无进展生存期分别为5.1个月和3.8个月。
- SCRT+TMZ组总生存期RMST增益在30个月时达+2.50个月(95% CI 1.74–3.31),无进展生存期RMST增益在10个月时达+1.58个月(95% CI 1.16–2.01)。
关键数值与推荐
- 纳入标准:年龄≥65岁、新诊断组织学确诊胶质母细胞瘤、直接比较SCRT与SCRT+TMZ、提供总生存期或无进展生存期的Kaplan–Meier生存曲线。
- 患者平均年龄71.5岁,53.2%的患者Karnofsky体能状态评分<80。
临床怎么用
- 对于老年新诊断胶质母细胞瘤患者,SCRT联合TMZ可作为改善生存的治疗选择,尤其适用于体能状态尚可者。
局限性
- 仅纳入5项研究,证据有限,需更多临床试验补充。
- 采用伪个体患者数据从生存曲线数字化重建,可能存在信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Glioblastoma is the most common and aggressive primary brain tumor in adults, with elderly patients facing particularly poor outcomes due to frailty and treatment intolerance. Short-course radiotherapy (SCRT) is a pragmatic approach, but the added benefit of temozolomide (TMZ) to SCRT is supported by limited evidence. METHODS: We conducted a search of PubMed, SCOPUS and Embase for studies published from inception to July 9, 2025. Eligible studies directly compared SCRT to SCRT + TMZ in elderly adults (≥ 65years) with newly diagnosed, histologically confirmed glioblastoma, and provided Kaplan–Meier survival curves for overall survival (OS) or progression-free survival (PFS). Pseudo-individual patient data were digitized from published survival curves and survival curves were reconstructed. Hazard ratios (HRs) were estimated with a one stage Cox regression analyses and differences in restricted mean survival time (ΔRMST) were analyzed. RESULTS: Initial search yielded 211 articles, out of which five studies (1,062 patients; 516 SCRT + TMZ, 546 SCRT) met inclusion for analysis. Mean age was 71.5 years with 53.2% of patients having Karnofsky Performance Status < 80. SCRT + TMZ significantly reduced the hazard of death (HR: 0.68, 95% CI: 0.70–0.77; p < 0.0001) and disease progression (HR 0.53, 95% CI 0.45–0.62, p < 0.0001). The median OS was longer with SCRT + TMZ than with SCRT alone (8.0 months vs. 6.1 months), as was the median PFS (5.1 months vs. 3.8 months). SCRT + TMZ showed increasing survival benefits with significant ΔRMST for OS of up to + 2.50 months at 30 months (95% CI: 1.74–3.31). PFS gains were also significant, with ΔRMST of up to + 1.58 months (95% CI: 1.16–2.01) at 10 months. CONCLUSION: In elderly patients with newly diagnosed glioblastoma, SCRT + TMZ significantly improves OS and PFS compared with SCRT alone with increasing survival benefits over time. There is the need for more clinical trials to supplement the available evidence.
引用
- Darko K, Chen J, Eckel-Passow JE, et al. Short-course radiotherapy with or without temozolomide in elderly patients with newly diagnosed glioblastoma: a time-to-event meta-analysis of overall and progression-free survival. J Neurooncol. 2025. PMID: 41307742. doi:10.1007/s11060-025-05352-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。